TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Submission of Matters to a Vote of Security Holders

61

TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security
Holders.

On May17, 2017, the Company held its Annual Meeting of
Stockholders in King of Prussia, Pennsylvania. Of the 57,129,584
shares outstanding as of the March20, 2017 record date,
49,272,809 shares, or approximately 86.2%, were present or
represented by proxy at the Annual Meeting. With respect to the
matters submitted for a vote of stockholders at the Annual
Meeting: (i)each of the ClassI directors nominated were elected
to serve and (ii)the selection of Ernst Young LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017 was ratified. Set forth below are the
voting results for each such matter.

Proposal 1 Election of Directors

The following three ClassI directors were elected to serve for
three-year terms until the 2020 annual meeting of stockholders
and until their respective successors are elected and qualified.

Name

VotesFor

VotesWithheld

BrokerNon-Votes

Adam M. Koppel, M.D., Ph.D.

35,162,613

169,898

13,940,298

Anne M. Phillips, M.D.

35,155,245

177,266

13,940,298

Barbara Yanni

35,160,022

172,489

13,940,298

Proposal 2 Ratification of the selection of Ernst Young LLP
as the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017.

For

Against

Abstain

BrokerNon-Votes

49,089,470

145,943

37,396


About TREVENA, INC. (NASDAQ:TRVN)

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

TREVENA, INC. (NASDAQ:TRVN) Recent Trading Information

TREVENA, INC. (NASDAQ:TRVN) closed its last trading session down -0.01 at 3.09 with 365,066 shares trading hands.

An ad to help with our costs